Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.42 |
| ▸ | HTR2A | P28223 | 12/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818062 | 0.84 | HTR2C (0.61) | HTR2CHTR2ACYP1A2HTR2BCYP3A4 | |
| SCHEMBL30404414 | 0.82 | HTR2C (0.44) | HTR2CHTR2ACYP1A2HTR2BCYP3A4 | |
| SCHEMBL25301683 | 0.82 | HTR2C (0.44) | HTR2CHTR2ACYP1A2HTR2BCYP3A4 | |
| SCHEMBL24110216 | 0.82 | HTR2C (0.44) | HTR2CHTR2ACYP1A2HTR2BCYP3A4 | |
| SCHEMBL25818032 | 0.81 | HTR2C (0.41) | HTR2CHTR2ACYP1A2HTR2BCYP3A4 | |
| SCHEMBL25818067 | 0.75 | HTR2A (0.38) | HTR2CHTR2ACYP1A2HTR2B | |
| SCHEMBL25296623 | 0.75 | HTR2C (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL24110218 | 0.75 | HTR2C (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL25818074 | 0.75 | HTR2C (0.37) | HTR2CHTR2ACYP1A2HTR2BHPGD | |
| SCHEMBL30839298 | 0.73 | HTR2C (0.69) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2C 35/4885HTR2A 10/4885CYP1A2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.